FDA-Approved Ovarian Cancer Treatments

FDA-APPROVED OVARIAN CANCER TREATMENTS
Generic	Brand	Strength	Form	Usual Dose
Alkylating agent
altretamine	Hexalen	50mg	caps	260mg/m² daily in four divided doses for either 14 or 21 consecutive days in a 28-day cycle
carboplatin	—	10mg/ mL	soln for IV infusion	Advanced ovarian cancer (previously untreated): 300mg/m² on Day 1 every 4wks for 6 cycles Recurrent ovarian cancer: 360mg/m² on Day 1 every 4wks
cisplatin	—	1mg/mL	soln for IV infusion after dilution	75–100mg/m² IV per cycle once every 3–4wks on Day 1
cisplatin	—	50mg/vial	pwd for IV infusion after reconstitution and dilution	75–100mg/m² IV per cycle once every 3–4wks on Day 1
cyclophos– phamide	—	25mg, 50mg	tabs	1–5mg/kg/day
cyclophos– phamide	—	500mg, 1g, 2g	pwd for inj after reconsti– tution	40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan	Alkeran	2mg	scored tabs	0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa	—	15mg	pwd for IV, intravesical, or intracavitary admini– stration after reconsti– tution	0.3–0.4mg/kg IV once every 1–4wks
Antibiotics (cytotoxic)
doxorubicin	—	10mg, 20mg, 50mg	pwd for IV inj after reconsti– tution	Monotherapy: 60–75mg/m² every 21 days Combination therapy: 40–60mg/m² every 21 to 28 days
doxorubicin	—	2mg/mL	soln for IV inj
doxorubicin (liposomal)	Doxil	2mg/mL	dispersion for IV infusion after dilution	50mg/m² once every 4wks; continue for ≥4 cycles as tolerated. Initial rate: 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur.
Antimetabolite
gemcitabine	Gemzar	200mg, 1g	pwd for IV infusion after reconsti– tution	1000mg/m² on Days 1 and 8 of each 21-day cycle; give with carboplatin AUC 4 administered on Day 1 after gemcitabine
gemcitabine	Infugem	1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL	soln for IV infusion
Antimicrotubule agents
paclitaxel	—	6mg/mL	soln for IV infusion after dilution	Previously untreated ovarian cancer: 175mg/m² IV over 3hrs + cisplatin; or 135mg/m² IV over 24hrs + cisplatin; repeat every 3wks Previously treated ovarian cancer: 135mg/m² or 175mg/m² over 3hrs every 3wks
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR
niraparib	Zejula	100mg	caps	300mg once daily until disease progression or unacceptable toxicity
olaparib	Lynparza	100mg, 150mg	tabs	300mg twice daily. First-line maintenance of BRCA-mutated advanced ovarian: continue until disease progression, unacceptable toxicity, or completion of 2yrs of treatment. Discontinue if complete response at 2yrs; may treat beyond 2yrs in those with evidence of disease if provider can derive further benefit from continuous treatment. Maintenance of recurrent ovarian or germline BRCA-mutated advanced ovarian: continue until disease progression or unacceptable toxicity.
rucaparib	Rubraca	200mg, 250mg, 300mg	tabs	600mg twice daily until disease progression or unacceptable toxicity
Topoisomerase inhibitor
topotecan	Hycamtin	4mg	pwd for IV infusion after reconsti– tution and dilution	1.5mg/m² daily for 5 consecutive days starting on Day 1 of a 21-day cycle
NOTES

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. (Rev. 4/2020)

Want to read more?